Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Vibegron - A Novel Treatment for Multisystem Functional Decline in Aging and Obesity

Authors not listed

Wake Forest University Health Sciences · 2026

Abstract

This 12-week randomized, double-blind, placebo-controlled trial will test the hypothesis that Vibegron (brand name GEMTESA) can improve energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-29 MST

Cite this

APA
Anonymous. (2026). Vibegron - A Novel Treatment for Multisystem Functional Decline in Aging and Obesity. <em>Wake Forest University Health Sciences</em>. https://clinicaltrials.gov/study/NCT06987383
Vancouver
Anonymous. Vibegron - A Novel Treatment for Multisystem Functional Decline in Aging and Obesity. Wake Forest University Health Sciences. 2026.
BibTeX
@misc{anon2026Vibegr, title = {Vibegron - A Novel Treatment for Multisystem Functional Decline in Aging and Obesity}, author = {Anonymous}, journal = {Wake Forest University Health Sciences}, year = {2026}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings